- Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Eli Lilly and Company
- Eli Lilly’s obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval CNBC
- Lilly’s Obesity Pill Cut Body Weight by 11% in Key Study Bloomberg.com
- Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says CNN
- Pill Causes Major Weight Loss in Eli Lilly Trial’s Results The New York Times
Source link
